HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 12-10-2004, 08:38 PM   #1
Guest
Guest
 
Posts: n/a
http://www.abstracts2view.com/sabcs/sessionindex.php

[1110] High pathological complete remission rate following neoadjuvant taxane, carboplatin and trastuzumab therapy after doxorubicin and cyclophosphamide in Her-2 positive breast cancer patients.

Mehta RS, Schubbert T, Hsiang D, Su L, Carpenter P, Holcombe R, Butler J, Baick C. Univeristy of California, Irvine, Orange, CA

Background: A pathological complete remission (pCR), a surrogate of improved survival, is achieved in a minority of breast cancer (BC) patients after neoadjuvant doxorubicin and cyclophosphamide (AC). Recently, targeted therapy using a taxane, carboplatin and trastuzumab (TCH) regimen has shown improved clinical outcome in patients with Her-2 positive stage IV BC. We hypothesized that targeted therapy with TCH will synergize with or overcome resistance to AC in the neoadjuvant setting. Materials and Method: A retrospective review of 8 consecutive locally advanced (stage: 4, IIIA; 3, IIIB; 1, IV), Her-2 positive (IHC 3+) BC patients enrolled into our IRB approved imaging studies was performed. Pretreatment average tumor size was 6.8 cm. All patients received 2 to 4 cycles of AC. The first 2 patients received a taxane following AC prior to 4 cycles of 3-weekly TCH regimen. The next 6 patients received dose dense AC with growth factor support as initial treatment followed by weekly TCH (T-80mg/m2, C-AUC of 2, H-4mg/kg then 2mg/kg, 14 average doses). At the end of AC-TCH therapy, patients had definitive surgery. Results: Seven of 8 patients demonstrated pCR following TCH even though they had variable responses (3-major clinical response; 4-no response; 1-relapse) to AC. Only 1 of 8 patients had a 3 mm residual invasive carcinoma in the biopsy scar. Moreover, 7 of 7 patients with palpable lymph nodes demonstrated no residual cancer. Seven patients remain progression free and all 8 patients are alive at a median follow up of 14 months (range 6-22) from the time of diagnosis. None of the patients had clinical cardiac dysfunction or neutropenic fever. Discussion: Our results indicate that AC followed by a short course of TCH induces a high rate of pCR in Her-2 positive patients. Given this high pCR rate, we speculate that the AC-TCH sequential regimen targets both topoisomerase II amplified and deleted clones, respectively, in Her-2 positive BC patients. Absence of clinical cardiac dysfunction in our patients suggests relative safety of sequential use of AC and TCH.

Wednesday, December 8, 2004 4:30 PM

Late Acceptances and Rescheduled Posters (4:30 PM-7:00 PM)
  Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 02:32 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter